COPD Therapeutics Market Outlook:
COPD Therapeutics Market size was valued at USD 23.7 billion in 2025 and is projected to reach USD 51.17 billion by the end of 2035, rising at a CAGR of 8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of COPD therapeutics is assessed at USD 25.6 billion.
The COPD therapeutics market is fueled by a large and increasing number of global patients. The World Health Organization statistics in November 2024 put the estimate of deaths due to COPD in 2021 at 3.5 million, ranking it as the fourth leading cause of death. This widespread prevalence generates a regular and large-scale demand for drug interventions. The supply chain for these medicines is internationally integrated, including the manufacture of Active Pharmaceutical Ingredients (APIs) and the production of sophisticated drug delivery devices such as inhalers. Further, most of the API manufacturing is seen in Asia, with the U.S. as the primary importer.
Investment in research, development, and deployment is high, as the National Institutes of Health (NIH) has spent considerable amounts on respiratory disease-related research. For example, the IBEF report of May 2025 illustrates that Rs. 2,61,900 crores are invested in India's healthcare and pharmaceutical industry during 2022-2024, which has enhanced the country's drug-making ecosystem, clinical research capability, and inhalation therapy innovation. A portion of these funds has supported the development and scaling of respiratory care solutions, including COPD therapeutics such as inhalers, bronchodilators, and combination drugs.
